Seeking Alpha

Cempra (CEMP +3.6%) rises after getting a five year contract worth up to $58M to develop its...

Cempra (CEMP +3.6%) rises after getting a five year contract worth up to $58M to develop its lead product candidate solithromycin (an antibiotic under development for the treatment of community-acquired bacterial pneumonia) for use in pediatrics and as a defense against bioterrorism. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|